Enanta Pharma Presents Addl. Data From AbbVie's M13-393 Study

(RTTNews) - Biotechnology company Enanta Pharmaceuticals Inc. (ENTA) announced the presentation of additional data from AbbVie's M13-393 study, known as PEARL-I, at The Liver Meeting, the 64th Annual Meeting of the American Association for the Study of Liver Diseases in Washington, D.C.

The company noted that SVR12 rates of 95% in hepatitis C, or HCV, GT-1b treatment-naïve patients and 90% among prior null responders will be presented in the intent-to-treat analysis. In PEARL-I study, two patients in the treatment-naive arm did not achieve SVR12 due to loss to follow up. In the null responder arm, one patient experienced breakthrough and three patients relapsed.

PEARL-I is a phase-2b, interferon-free, 320 patient study being conducted by AbbVie to evaluate the once-daily, two-DAA regimen consisting of ABT-450/r, or protease inhibitor plus ritonavi, plus ABT-267, or AbbVie's NS5A inhibitor, in HCV treatment-naïve patients and treatment-experience patients.